Affiliations: [a] Roche Products Limited, Hexagon Place, 6 Falcon way, Shire Park, Welwyn Garden City, UK | [b] Institute of Psychiatry, King’s College London, De Crespigny Park, London, UK | [c] Janssen Pharmaceutical Research and Development, Titusville, NJ, USA | [d] Janssen Research & Development, LLC, Fremont, CA, USA | [e] Boehringer Ingelheim, Reims, France | [f] Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA
Correspondence:
[*]
Correspondence to: Nadia Foskett, Roche Products Limited, 6 Falcon Way, Shire Park, Welwyin Garden City AL7 1TW, UK. Tel.: +44 (0)777 166 0191; nadia.foskett@roche.com
Abstract: The prevalence of mild cognitive impairment (MCI) and dementia according to age remain uncertain. We systematically extracted age-stratified estimates of MCI and dementia prevalence reported in European studies published since 1995, and performed meta-analyses for dementia. We identified 10 relevant studies on MCI and 26 studies on dementia. Studies on MCI presented substantial heterogeneity preventing a meta-analysis, with a majority reporting an increase in prevalence at ≥75 years old. Pooled prevalence of dementia rose continuously from 55 years of age, reaching 44.7% (39.8; 49.6) in those ≥95 years of age. Homogenization of MCI criteria, and additional studies in Northern European population would be warranted.
